The Institute for Neurodegenerative Disorders (INDD) launched the Amadeus consortium (American and European Union SPECT Imaging Consortium) at a June investigators meeting in Florence, Italy.
The consortium is an international effort to apply standardized quantitative neuroimaging technology in multicenter clinical trials to improve diagnosis and evaluate treatments for Parkinson's disease (PD) and related disorders, the INDD said.
The group said will be validating imaging outcomes across study centers, validating SPECT imaging biomarkers for PD diagnosis and disease progression prior to and after symptoms have developed, and assessing new therapies in global multicenter imaging studies for neurodegenerative disorders.
Amadeus' first project will be a single-blinded assessment of the short-term effects of cabergoline versus carbidopa/levodopa on SPECT dopamine transporter density in patients with PD. The project is a multicenter study with 120 patients at 12 sites in five European countries designed to address whether common treatments for PD influence dopamine transporter imaging biomarkers of disease, according to the New Haven, CT-based INDD.
By AuntMinnie.com staff writersJuly 15, 2004
Related Reading
Dopamine transporter imaging with SPECT narrows Parkinsonian diagnosis, April 7, 2003
PET, SPECT confirm: In Parkinson's, dopamine agonists work better than levodopa, May 20, 2002
SPECT imaging can assess effect of Parkinson's disease treatment, April 3, 2002
Copyright © 2004 AuntMinnie.com
